KCK Ltd. disclosed in a regulatory filing ( SC 13G ) with the Securities and Exchange Commission (SEC) a 6.2% passive stake (1,818,181 shares) in Vital Therapies, Inc. (VTL).
For the third quarter 2015, Vital Therapies posted a net loss of ($12.3) million, or ($0.51) per share, compared to a net loss of ($12.8) million, or ($0.59) per share in the same period the prior year
Vital Therapies is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure.
Brokerage firm WallachBeth upgraded shares of VIVUS Inc. (VVUS) from a Hold to a Buy rating and raised its price target from $2.30 to $2.80
VIVUS delivered third quarter 2015 revenue of $24.9 million and a net loss of ($16.1) million, or ($0.15) per share, topping the Capital IQ Consensus Estimate of ($0.18) loss per share on revenues of $20.2 million for the period
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer